Literature DB >> 24610744

Active surveillance for clinically localized prostate cancer--a systematic review.

Frederik B Thomsen1, Klaus Brasso, Laurence H Klotz, M Andreas Røder, Kasper D Berg, Peter Iversen.   

Abstract

Active surveillance (AS) has been introduced as an observational strategy to delay or avoid curative treatment without compromising long-term cancer-specific survival. The 10 studies included in this review, published between 2008 and 2013, generally agreed upon patients selection for the AS strategy and how they should be managed within the program. However, uncertainties persists concerning optimal patient selection and reliable progression criteria, as well as the long-term safety of AS.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  active surveillance; progression criteria; prostate cancer; selection criteria; systematic review

Mesh：

Year:  2014        PMID： 24610744     DOI： 10.1002/jso.23584

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN： 0022-4790            Impact factor:   3.454


  43 in total

1.  [Primum nil nocere].

Authors:  C Roloff
Journal:  Urologe A       Date:  2015-10       Impact factor: 0.639

2.  Final pathohistology after radical prostatectomy in patients eligible for active surveillance (AS).

Authors:  Ekaterina Lellig; Christian Gratzke; Alexander Kretschmer; Christian Stief
Journal:  World J Urol       Date:  2015-06-06       Impact factor: 4.226

3.  Robot-assisted radical prostatectomy in low- and high-risk prostate cancer patients.

Authors:  Uğur Boylu; Ahmet Bindayi; Eyüp Veli Küçük; Fikret Fatih Önol; Eyüp Gümüş
Journal:  Turk J Urol       Date:  2017-01-06

4.  Radical prostatectomy versus deferred treatment for localised prostate cancer.

Authors:  Robin Wm Vernooij; Michelle Lancee; Anne Cleves; Philipp Dahm; Chris H Bangma; Katja Kh Aben
Journal:  Cochrane Database Syst Rev       Date:  2020-06-04

Review 5.  Vascular targeted photochemotherapy using padoporfin and padeliporfin as a method of the focal treatment of localised prostate cancer - clinician's insight.

Authors:  Andrzej M Bugaj
Journal:  World J Methodol       Date:  2016-03-26

6.  HAROW: the first comprehensive prospective observational study comparing treatment options in localized prostate cancer.

Authors:  Lothar Weissbach; Steffen Stuerzebecher; Eberhard Mumperow; Theodor Klotz; Dietrich Schnell
Journal:  World J Urol       Date:  2015-09-15       Impact factor: 4.226

7.  The Treatment of Localized Prostate Cancer in Everyday Practice in Germany.

Authors:  Jan Herden; Lena Ansmann; Nicole Ernstmann; Dietrich Schnell; Lotharh Weißbac
Journal:  Dtsch Arztebl Int       Date:  2016-05-13       Impact factor: 5.594

8.  Genetic associations of T cell cancer immune response with tumor aggressiveness in localized prostate cancer patients and disease reclassification in an active surveillance cohort.

Authors:  Qinchuan Wang; Justin R Gregg; Jian Gu; Yuanqing Ye; David W Chang; John W Davis; Timothy C Thompson; Jeri Kim; Christopher J Logothetis; Xifeng Wu
Journal:  Oncoimmunology       Date:  2018-10-29       Impact factor: 8.110

9.  Outcomes of men with an elevated prostate-specific antigen (PSA) level as their sole preoperative intermediate- or high-risk feature.

Authors:  Farzana A Faisal; Debasish Sundi; Phillip M Pierorazio; Mark W Ball; Elizabeth B Humphreys; Misop Han; Jonathan I Epstein; Alan W Partin; H Ballentine Carter; Trinity J Bivalacqua; Edward M Schaeffer; Ashley E Ross
Journal:  BJU Int       Date:  2014-08-13       Impact factor: 5.588

Review 10.  [Demographic change: Changes in society and medicine and developmental trends in geriatrics].

Authors:  G F Kolb; L Weißbach
Journal:  Urologe A       Date:  2015-12       Impact factor: 0.639
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.